In the Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations

Pharmaceutical Technology
Volume 33, Issue 6, pp. 28

Editors' Picks of Pharmaceutical Science & Technology Innovations

Drugmakers never stop looking for components and equipment that will create therapies more quickly, more reliably, and more efficiently. The industry's need pushes pharmaceutical and biopharmaceutical manufacturing technology to evolve continually. This month's featured products are designed to improve the speed and flexibility of the pharmaceutical production line. Continental Disc's rupture discs can withstand harsh conditions. Thomas Engineering has unveiled a tablet coater designed to facilitate cleaning validation and reduce contamination. And Millipore's membrane adsorber can remove impurities at high salt concentrations.

Tablet coater provides flexibility


Accela-Cota Flex 500 tablet coater Thomas Engineering www.thomaseng.com
The Accela-Cota Flex 500 production-class tablet coater from Thomas Engineering (Hoffman Estates, IL) incorporates drums that can be removed and exchanged in 30 min without tools. This feature lets operators dedicate a drum to a particular product, thus facilitating cleaning validation and reducing risk of cross contamination. The tablet coater accepts drums of various sizes, allowing users to choose the right drum for the process they must perform. Removing the drums enables operators to clean the inside of the coater thoroughly. The machine's mixing baffles are also interchangeable.

Rupture disc withstands severe conditions


SanitRX MP rupture disc Continental Disc www.contdisc.com
Continental Disc (Liberty, MO) has added the MP unit to its SanitRX series of rupture discs. The product was designed for applications during which conditions frequently change between positive pressure and vacuum. The company moved the disc's score line from the contact side to the downstream side so that it is subject to less stress when pressure changes. The new position also improves the disc's cleanability. The disc can be cleaned or steamed in place.

The disc complies with the American Society for Mechanical Engineers's bioprocessing equipment criteria for process-side surface finish and fully traceable metal and elastomer materials. The component also is free of polishing compounds, release agents, and animal derivatives. The disc is appropriate for pressure-vessel applications such as autoclaves, fermenters, and heat exchangers.

Membrane adsorber uses nontraditional chemistry


ChromaSorb membrane adsorber Millipore www.millipore.com
The ChromaSorb solution is a single-use anion-exchange membrane adsorber from Millipore (Billerica, MA) designed to remove negatively charged impurities. The product has greater binding strength at high salt concentrations than traditional resins and current membranes, according to the company. This strength results from a primary-amine gel with a high charge density that coats the adsorber's base membrane. The gel provides many areas of contact for negatively charged impurities such as host-cell proteins and viruses to bind.

Because ChromaSorb devices can continue to bind at high salt concentrations, no product dilution is required. The ChromaSorb product is designed for flow-through applications at the polishing step of the purification of monoclonal antibodies and recombinant proteins.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here